Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine SR in Canadian Subjects With Multiple Sclerosis Who Participated in Acorda Extension Trials

NCT01235221 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01235221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01235221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine SR in Canadian Subjects With Multiple Sclerosis Who Participated in Acorda Extension Trials
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
June 30, 2012
Enrollment
38 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis